Sinovac Biotech Ltd. (NASDAQ: SVA) (“Sinovac " or the “Company”), a leading provider of biopharmaceutical products in China, today announced preliminary results of a phase III clinical study on Sabin inactivated polio vaccine (“sIPV”) developed by Sinovac Biotech Co., Ltd. (“Sinovac Beijing”) on the unblinding conference held on April 19, 2018.
April 19, 2018
· 4 min read